Published in Mov Disord on September 15, 2010
Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology (2011) 1.45
c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's Disease. Front Pharmacol (2016) 0.90
High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. J Neural Transm (Vienna) (2011) 0.81
The associations between Parkinson's disease and cancer: the plot thickens. Transl Neurodegener (2015) 0.81
The association between Parkinson's disease and melanoma: a systematic review and meta-analysis. Transl Neurodegener (2015) 0.80
Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Mov Disord (2013) 0.79
Cancer in Parkinson's disease. Parkinsonism Relat Disord (2016) 0.75
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA (2012) 5.40
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med (2013) 4.11
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A (2004) 3.73
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet (2005) 3.63
Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology (2013) 3.61
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disord (2005) 2.88
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol (2003) 2.81
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Diagnosis and management of pergolide-induced fibrosis. Mov Disord (2004) 2.63
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology (2005) 2.25
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol (2007) 2.06
Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol (2009) 2.06
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01